Vivos Therapeutics (VVOS) Liabilities and Shareholders Equity (2019 - 2026)

Vivos Therapeutics (VVOS) has 8 years of Liabilities and Shareholders Equity data on file, last reported at $25.0 million in Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $25.0 million, up 121.97% year-over-year; the trailing twelve-month figure through Mar 2026 was $101.9 million (up 76.39% YoY), and the FY2025 annual result was $25.2 million, up 64.56% from the prior year.
• Liabilities and Shareholders Equity held at $25.0 million in Q1 2026 per VVOS's latest filing, from $25.2 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $29.6 million in Q1 2022 and troughed at $10.3 million in Q3 2023.
• A 5-year average of $18.2 million and a median of $15.8 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2022 and 2026: Liabilities and Shareholders Equity sank 59.27% in 2022, then surged 121.97% in 2026.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $13.7 million in 2022, then declined by 21.79% to $10.7 million in 2023, then jumped by 42.44% to $15.3 million in 2024, then surged by 64.56% to $25.2 million in 2025, then declined by 0.43% to $25.0 million in 2026.
• Business Quant data shows VVOS's Liabilities and Shareholders Equity at $25.0 million in Q1 2026, $25.2 million in Q4 2025, and $25.6 million in Q3 2025.